ATE420654T1 - Behandlung von muskeldystrophien und verwandter erkrankungen - Google Patents
Behandlung von muskeldystrophien und verwandter erkrankungenInfo
- Publication number
- ATE420654T1 ATE420654T1 AT02757182T AT02757182T ATE420654T1 AT E420654 T1 ATE420654 T1 AT E420654T1 AT 02757182 T AT02757182 T AT 02757182T AT 02757182 T AT02757182 T AT 02757182T AT E420654 T1 ATE420654 T1 AT E420654T1
- Authority
- AT
- Austria
- Prior art keywords
- abnormal
- treatment
- related diseases
- activity
- diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 210000003205 muscle Anatomy 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 abstract 4
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 2
- 108010069440 Dystrophin-Associated Protein Complex Proteins 0.000 abstract 2
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000004954 Biglycan Human genes 0.000 abstract 1
- 108090001138 Biglycan Proteins 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 101710190051 Muscle, skeletal receptor tyrosine protein kinase Proteins 0.000 abstract 1
- 102100038168 Muscle, skeletal receptor tyrosine-protein kinase Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000715 neuromuscular junction Anatomy 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31255101P | 2001-08-15 | 2001-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE420654T1 true ATE420654T1 (de) | 2009-01-15 |
Family
ID=23211978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02757182T ATE420654T1 (de) | 2001-08-15 | 2002-08-15 | Behandlung von muskeldystrophien und verwandter erkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7759314B2 (de) |
| EP (1) | EP1423133B1 (de) |
| AT (1) | ATE420654T1 (de) |
| AU (1) | AU2002323217B2 (de) |
| CA (1) | CA2455884C (de) |
| DE (1) | DE60230877D1 (de) |
| WO (1) | WO2003015615A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612038B2 (en) | 1999-11-18 | 2009-11-03 | Brown University | Biglycan and related therapeutics and methods of use |
| US6864236B1 (en) | 1999-11-18 | 2005-03-08 | Brown University Research Foundation | Biglycan and related therapeutics and methods of use |
| WO2003015615A2 (en) | 2001-08-15 | 2003-02-27 | Brown University Research Foundation | Treatment of muscular dystrophies and related disorders |
| LT2280720T (lt) * | 2008-03-27 | 2019-07-25 | Purdue Research Foundation | Kolageną surišantys sintetiniai peptidoglikanai, jų paruošimas ir naudojimo būdai |
| US20110224128A1 (en) * | 2009-04-13 | 2011-09-15 | Anne Whalen | Methods and compositions for treatment of muscular dystrophy |
| KR100983182B1 (ko) * | 2009-08-14 | 2010-09-20 | (주)엔솔테크 | 신규 펩타이드 및 그 용도 |
| BR112012007137A2 (pt) | 2009-09-30 | 2015-09-15 | Harvard College | metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia |
| EP2571514B1 (de) | 2010-05-17 | 2018-07-18 | Brown University | Biglycan-mutanten sowie entsprechende therapiemittel und verwendungsverfahren dafür |
| CA2823194A1 (en) | 2010-12-27 | 2012-07-05 | Brown University | Therapeutic and diagnostic methods involving biglycan and utrophin |
| PT2714718T (pt) | 2011-05-24 | 2017-04-19 | Symic Ip Llc | Preparação e métodos de utilização de peptidoglicanas sintéticas que se ligam a ácido hialurónico |
| EP2717902B1 (de) | 2011-06-06 | 2018-01-24 | Phasebio Pharmaceuticals, Inc. | Verwendung modifizierter vasoaktiver darmpeptide bei der behandlung von bluthochdruck |
| EP2970509B1 (de) | 2013-03-15 | 2020-05-13 | Purdue Research Foundation | Extrazelluläre matrix zur bindung synthetischer peptidglycane |
| WO2015164822A1 (en) | 2014-04-25 | 2015-10-29 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
| CA2947982C (en) | 2014-05-08 | 2022-11-29 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
| CN107427556B (zh) | 2015-02-09 | 2022-02-25 | 费斯生物制药公司 | 用于治疗肌肉疾病和病症的方法和组合物 |
| CA3005633C (en) | 2015-11-16 | 2023-11-21 | Research Institute Of Nationwide Children's Hospital | Materials and methods for treatment of titin-based myopathies and other titinopathies |
| WO2018067449A1 (en) * | 2016-10-05 | 2018-04-12 | Bio-Techne Corporation | Methods and kits for assaying endoglycosidase activity |
| JP2020526497A (ja) | 2017-07-07 | 2020-08-31 | サイミック アイピー， エルエルシー | 合成バイオコンジュゲート |
| CN112543810A (zh) | 2018-06-29 | 2021-03-23 | 全国儿童医院研究所 | 治疗肢带型肌营养不良2a型的重组腺相关病毒产品和方法 |
| AU2019337338A1 (en) * | 2018-09-10 | 2021-04-08 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | Musk inhibition |
| CN113766935A (zh) | 2019-02-26 | 2021-12-07 | 全国儿童医院研究所 | β-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗 |
| EP3955742A4 (de) | 2019-04-18 | 2023-05-24 | Brown University | Neurogenese |
| EP4045031A4 (de) * | 2019-10-16 | 2023-11-29 | Brown University | Muskelregeneration und -wachstum |
| CN118290567A (zh) * | 2023-08-28 | 2024-07-05 | 科兴生物制药股份有限公司 | 重组人源化iii型三螺旋胶原蛋白及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705609A (en) | 1988-06-28 | 1998-01-06 | La Jolla Cancer Research Foundation | Decorin fragments inhibiting cell regulatory factors |
| US5654270A (en) * | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
| ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5340934A (en) | 1989-11-03 | 1994-08-23 | The United States Of Americas As Represented By The Secretary Of Health & Human Services | CDNA sequences of human bone matrix proteins |
| JP3854307B2 (ja) | 1991-12-04 | 2006-12-06 | ザ バーナム インスティテュート | 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害 |
| US5955265A (en) | 1992-02-06 | 1999-09-21 | Massachusetts Institute Of Technology | DNA sequence encoding the myotonic dystrophy gene and uses thereof |
| ATE274340T1 (de) | 1993-08-10 | 2004-09-15 | Gore & Ass | Zelleinkapselungsvorrichtung |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| AU7200694A (en) | 1993-11-10 | 1995-05-29 | Worcester Foundation For Experimental Biology | Agrin receptor |
| AU6926194A (en) | 1994-05-09 | 1995-11-29 | Boehringer Mannheim Gmbh | Use of chondroitin sulphate proteoglycans for protection of neurons |
| US5882868A (en) | 1997-04-14 | 1999-03-16 | The Nemours Foundation | Method of diagnosing spinal muscular atrophy |
| EP1161258A1 (de) * | 1999-03-17 | 2001-12-12 | EntreMed, Inc. | Zusammensetzungen und verfahrungen von ldl rezeptor oder dergleichen liganden zur behandlung von krebs und angiogenischen erkrankungen |
| US7612038B2 (en) | 1999-11-18 | 2009-11-03 | Brown University | Biglycan and related therapeutics and methods of use |
| CA2738796C (en) * | 1999-11-18 | 2017-10-31 | Brown University Research Foundation | Biglycan and uses thereof in stabilizing dystrophin associated protein complexes |
| US6864236B1 (en) | 1999-11-18 | 2005-03-08 | Brown University Research Foundation | Biglycan and related therapeutics and methods of use |
| WO2003015615A2 (en) | 2001-08-15 | 2003-02-27 | Brown University Research Foundation | Treatment of muscular dystrophies and related disorders |
| WO2007123848A2 (en) | 2006-04-19 | 2007-11-01 | Brown University | Therapeutic compositions containing modified class i slrp proteins |
| WO2008100789A2 (en) | 2007-02-16 | 2008-08-21 | Benaroya Research Institute At Virginia Mason | Compositions and methods for altering elastogenesis |
| EP2571514B1 (de) | 2010-05-17 | 2018-07-18 | Brown University | Biglycan-mutanten sowie entsprechende therapiemittel und verwendungsverfahren dafür |
-
2002
- 2002-08-15 WO PCT/US2002/026201 patent/WO2003015615A2/en not_active Ceased
- 2002-08-15 DE DE60230877T patent/DE60230877D1/de not_active Expired - Lifetime
- 2002-08-15 CA CA2455884A patent/CA2455884C/en not_active Expired - Fee Related
- 2002-08-15 EP EP02757182A patent/EP1423133B1/de not_active Expired - Lifetime
- 2002-08-15 AU AU2002323217A patent/AU2002323217B2/en not_active Ceased
- 2002-08-15 US US10/486,678 patent/US7759314B2/en not_active Expired - Fee Related
- 2002-08-15 AT AT02757182T patent/ATE420654T1/de not_active IP Right Cessation
-
2010
- 2010-05-24 US US12/786,294 patent/US8822418B2/en not_active Expired - Fee Related
-
2014
- 2014-08-29 US US14/473,834 patent/US20150182589A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1423133B1 (de) | 2009-01-14 |
| CA2455884C (en) | 2015-09-22 |
| EP1423133A2 (de) | 2004-06-02 |
| DE60230877D1 (de) | 2009-03-05 |
| US20150182589A1 (en) | 2015-07-02 |
| WO2003015615A9 (en) | 2003-08-07 |
| CA2455884A1 (en) | 2003-02-27 |
| US20110053854A1 (en) | 2011-03-03 |
| US20050043221A1 (en) | 2005-02-24 |
| EP1423133A4 (de) | 2006-03-01 |
| WO2003015615A2 (en) | 2003-02-27 |
| AU2002323217B2 (en) | 2008-04-10 |
| US8822418B2 (en) | 2014-09-02 |
| WO2003015615A3 (en) | 2003-11-13 |
| US7759314B2 (en) | 2010-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE420654T1 (de) | Behandlung von muskeldystrophien und verwandter erkrankungen | |
| DE60027762D1 (de) | Diagnose und behandlung von arthritischen erkrankungen | |
| DE602005019874D1 (de) | Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors | |
| DE60236206D1 (de) | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren | |
| NO20010446L (no) | Substituert anilidforbindelser og metoder | |
| ES2178668T3 (es) | Naftilamidas como agentes del sistema nervioso central. | |
| TR200103104T2 (tr) | Glukortikoid alıcı modülatörleri | |
| ATE443699T1 (de) | Pyridine zur behandlung von verletztemsäugetiernervengewebe | |
| DE69738613D1 (de) | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten | |
| DE59810761D1 (de) | Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| ATE355054T1 (de) | Verfahren und verbindungen zur behandlung der depression | |
| TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
| DE60126248D1 (de) | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| WO2003070195A3 (en) | Biglycan and related therapeutics and methods of use | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
| WO2004047727A3 (en) | Compositions and methods for diagnosing and treating mood disorders | |
| WO2001036475A3 (en) | Biglycan and related therapeutics and methods of use | |
| ATE232739T1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |